NCT04602754View on ClinicalTrials.gov

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

PHASE3RecruitingINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

August 31, 2025

Conditions
Dyslipidemia Associated With Type II Diabetes Mellitus
Interventions
DRUG

BERLIM 25/20 ASSOCIATION

Berlim 25/20 association coated tablet.

OTHER

EMPAGLIFLOZIN PLACEBO

Empagliflozin placebo coated tablet.

OTHER

ROSUVASTATIN CALCIUM PLACEBO

Rosuvastatin calcium placebo coated tablet.

DRUG

EMPAGLIFLOZIN

Empagliflozin 25 mg coated tablet.

DRUG

ROSUVASTATIN CALCIUM

Rosuvastatin 20 mg coated tablet.

OTHER

BERLIM 25/20 ASSOCIATION PLACEBO

Berlim 25/20 association placebo coated tablet.

Trial Locations (1)

Unknown

RECRUITING

Allergisa, Campinas

Sponsors

Lead Sponsor

EMS
All Listed Sponsors
lead

EMS

INDUSTRY